Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
Blood Cancer J
.
2022 Jun 28;12(6):97.
doi: 10.1038/s41408-022-00693-7.
Authors
Saurabh Zanwar
1
,
Jithma P Abeykoon
1
,
Surendra Dasari
1
,
Aishwarya Ravindran
2
,
Jason R Young
3
,
Aldo A Acosta-Medina
4
,
Karen L Rech
2
,
Jonathan Schwartz
5
,
Aaron Mangold
6
,
Allison Rosenthal
7
,
N Nora Bennani
1
,
Mithun V Shah
1
,
Diana Morlote
8
,
Gaurav Goyal
9
,
Ronald S Go
10
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
2
Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
3
Department of Radiology, Mayo Clinic, Jacksonville, FL, USA.
4
Department of Medicine, Mayo Clinic, Rochester, MN, USA.
5
Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN, USA.
6
Department of Dermatology, Mayo Clinic, Scottsdale, AZ, USA.
7
Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
8
Division of Hematopathology, University of Alabama at Birmingham, Birmingham, AL, USA.
9
Division of Hematology-Oncology, Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. ggoyal@uabmc.edu.
10
Division of Hematology, Mayo Clinic, Rochester, MN, USA. go.ronald@mayo.edu.
PMID:
35764604
PMCID:
PMC9240055
DOI:
10.1038/s41408-022-00693-7
No abstract available
Publication types
Letter
MeSH terms
Humans
Mutation
Protein Kinase Inhibitors* / therapeutic use
Proto-Oncogene Proteins B-raf* / genetics
Substances
Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf
Grants and funding
P30 CA015083/CA/NCI NIH HHS/United States